Asthma in the era of COVID-19

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001182" target="_blank" >RIV/00064190:_____/23:10001182 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10469995

Výsledek na webu

<a href="https://www.resmedjournal.com/action/showPdf?pii=S0954-6111%2823%2900261-5" target="_blank" >https://www.resmedjournal.com/action/showPdf?pii=S0954-6111%2823%2900261-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.rmed.2023.107373" target="_blank" >10.1016/j.rmed.2023.107373</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Asthma in the era of COVID-19

Popis výsledku v původním jazyce

Since its global invasion in 2019, COVID-19 has affected several aspects of patients&apos; lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management. (C) 2023

Název v anglickém jazyce

Asthma in the era of COVID-19

Popis výsledku anglicky

Since its global invasion in 2019, COVID-19 has affected several aspects of patients&apos; lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management. (C) 2023

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

RESPIRATORY MEDICINE

ISSN

0954-6111

e-ISSN

1532-3064

Svazek periodika

218

Číslo periodika v rámci svazku

11/2023

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

—

Kód UT WoS článku

001076741000001

EID výsledku v databázi Scopus

2-s2.0-85170097023